The relationship of social determinants of health, Appalachian residence, and prostate cancer treatment delay among Tennessee adults is relatively unknown. We used multivariate logistic regression on 2005-2015 Tennessee Cancer Registry data of adults aged ≥18 diagnosed with prostate cancer.
Recent data has demonstrated that hypoxia drives an immunosuppressive tumour microenvironment (TME) via various mechanisms including hypoxia inducible factor (HIF)-dependent upregulation of programmed death ligand 1 (PD-L1).
To compare clinical outcome and quality of life (QoL) in octogenarian patients with muscle-invasive urothelial carcinoma (MIBC) either treated by radical cystectomy (RC) or transurethral resection of the tumor (TURBT).
This study aimed to assess the prognostic significance of pre-treatment lymphocyte-related systemic inflammatory biomarkers in upper tract urothelial carcinoma (UTUC) patients. This study included non-metastatic UTUC patients treated at our hospital between 2001 and 2013.
{{header-clinical-trials-navigation}} A Phase 1, Three-Part, Open-Label, Parallel-Cohort Safety and Tolerability Study of Relugolix in Combination With Abiraterone Acetate Plus a Corticosteroid, Apalutamide, or Docetaxel With or Without Prednisone in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer Condition: Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer […]
{{header-clinical-trials-navigation}} A Phase 2 Course Determining Study for Men With Hormone-Naïve Metastatic Prostate Cancer (HNMPCa) Condition: Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8 Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03821792 Sponsor: […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana-Farber Cancer Institute in Boston. I’m so excited to have here with me today, Dr. Shahneen Sandhu who is an Associate Professor of Medical Oncology at the Peter MacCallum in Melbourne, Australia. Thank you so much for being here with […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana Farber Cancer Institute. I am so excited to have here with me today, a good friend and colleague Dr. Lorelei Mucci, who is the Director of the Cancer Epidemiology and Cancer Prevention Program within the Department of Epidemiology at […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana-Farber Cancer Institute in Boston in the US. I’m so excited to have here with me today Dr. Amina Zoubeidi, who is a Senior Research Scientist at the Vancouver Prostate Center, as well as being a Professor in the Department […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana Farber Cancer Institute. I’m so excited to have here with me today, Dr. Neil Bander who is a Professor of Urologic Oncology at Weill Cornell in New York. Thank you so much for being here with me today. Neil […]
